Impact of underlying liver disease on unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors
Linda Y. Wu, Sarah Cappuyns, Amanda S. Loh, Sean Sun, Sara Lewis, Max W. Sung, Myron Schwartz, Josep M. Llovet, Deirdre Jill Cohen
Abstract
BACKGROUND: Immune checkpoint inhibitors (ICIs) are standard therapy for unresectable HCC, but many patients do not respond. Non-viral HCC, particularly non-alcoholic steatohepatitis (NASH), have been implicated in ICI resistance. METHODS: We reviewed 288 patients with unresectable HCC who received ICI from 1/2017 to 12/2021. The overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) between patients with viral HCC and non-viral HCC were compared using the full and Child Pugh (CP) class A only cohorts. RESULTS: In total, 206 patients (71.5%) had viral HCC (most HCV), and 82 patients had non-viral HCC. Non-viral HCC was associated with worse OS (HR 1.6, 95% CI: 1.1-2.1, P = 0.006) and PFS (HR 1.5, 95% CI: 1.2-2, P = 0.002) in univariate but not multivariate analyses. For the CP class A cohort, non-viral HCC was independently associated with worse OS (HR 1.8, 95% CI: 1.2-2.7, P = 0.005) and PFS (HR 1.9, 95% CI: 1.3-2.7, P < 0.001). Viral HCC and CP class A liver disease was associated with better ORR than non-viral HCC (38% vs. 16%, P = 0.001). CONCLUSIONS: Following ICI treatment, non-viral HCC correlated with worse OS, PFS, and ORR than viral HCC, particularly in patients with preserved liver function.